Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome- |
RCV000210062 | SCV001977485 | pathogenic | Neuronal ceroid lipofuscinosis 5 | 2021-08-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002282043 | SCV002570818 | pathogenic | Neuronal ceroid lipofuscinosis | 2022-07-13 | criteria provided, single submitter | clinical testing | Variant summary: CLN5 c.547C>T (p.Gln183X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251410 control chromosomes. c.694C>T has been reported in the literature in multiple homozygous individuals affected with Neuronal Ceroid-Lipofuscinosis (De Silva_2015, El Haddad_2012). These data indicate that the variant is very likely to be associated with disease. These papers also report loss of full-length protein via Western blot analysis from affected individuals fibroblasts. Two other clinical diagnostic laboratory or database have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
OMIM | RCV000210062 | SCV000265990 | pathogenic | Neuronal ceroid lipofuscinosis 5 | 2016-10-20 | no assertion criteria provided | literature only |